Blood
Articles in this Issue
CMV reactivation under foscarnet prophylaxis in cord blood transplantation: Increased NRM without impact on relapse or survival
Abstract Background: Cytomegalovirus (CMV) infection remains an important post-transplant complication despite improved management, partly d...
Ktx-1001, a potent, selective MMSET/NSD2 inhibitor, enhances immunomodulatory and immune-directed therapies in preclinical models of multiple myeloma
Abstract Background: In t(4;14) multiple myeloma (MM), the histone methyl transferase NSD2 is dysregulated due to translocation of the IgH s...
Two decades of risk directed therapy for childhood acute lymphoblastic leukemia in a resource limited setting: Lessons from a modified st. jude total XV protocol
Abstract Background Survival for pediatric acute lymphoblastic leukemia (ALL) now exceeds 80% in high-income countries (HICs) with risk-adapt...
Transient ATM inhibition enhances knock-in efficiency and long-term engraftment of genome-edited hematopoietic stem cells
Abstract Precise genome editing in hematopoietic stem cells (HSCs) holds immense potential for the treatment of genetic blood disorders, suc...
IL-39/IL-39R signaling drives acute graft-versus-host disease
Abstract Background: Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and non-relapse mortality (NRM) following allogen...
CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center
Abstract Background: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) is used in the treatment of relapsed/refractory hematologic malignanci...
T cell receptors targeting mutant NPM1 for adoptive cell therapy in acute myeloid leukemia
Abstract Background: Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor c...
Inhibitors of RAD51 as potential novel therapies in Acute Myeloid Leukemia
Abstract RAD51 is a highly conserved gene whose protein product, RAD51, is instrumental in the maintenance of genome integrity in eukaryotes...
Predictors of long-term survival in adolescents and young adults with acute lymphoblastic leukemia: 20 years of insight from a nationally representative database
Abstract Background: Adolescents and young adults (AYAs), defined as individuals aged 15–39, represent a unique group in hematology, often t...
Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood
Abstract Objectives: Aberrant DNA methylation (5mC) and hydroxymethylation (5hmC) patterns are hallmarks of acute myeloid leukemia (AML) and...
A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial
Abstract Background: Molecular failure (MF) after first line intensive chemotherapy (IC) in NPM1-mutated (NPM1m) acute myeloid leukemia (AML)...
Cellular features of graft vs host disease prophylaxis impact on CD4 T cell reconstitution post allo-HCT
Abstract Introduction: Immune reconstitution after allogeneic hematopoietic cell transplantation (allo-HCT) is required for protection from...
Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China
Abstract INTRODUCTION Renal impairment (RI) is a frequent complication in newly diagnosed multiple myeloma (NDMM). Recovery of renal functio...
Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121
Abstract Background: Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo CRISPR/Cas9 gene-edited, autologous cell therapy approved for...
Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.
Abstract Background: We previously described three subtypes of Waldenstrom's Macroglobulinemia (WM) using a multi-omic data set derived from...
Comparative outcomes of CAR-T cell therapy with and without autologous stem cell transplant consolidation in diffuse large B-cell lymphoma: A real-world propensity-matched analysis
Abstract Background: CAR-T cell therapy has transformed the treatment landscape of diffuse large B-cell lymphoma (DLBCL). Autologous stem ce...
Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Abstract Background: Myelofibrosis (MF) a myeloproliferative neoplasm is characterised by progressive splenomegaly, cytopenia, debilitating s...
Intermediate‑dose cytarabine is noninferior to high‑dose cytarabine for AML consolidation: A systematic review and meta‑analysis
Abstract Introduction: High-dose cytarabine (HiDAC) has long been the standard for consolidation in acute myeloid leukemia (AML) but is asso...
Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa
Abstract Hemophilia A is an X-linked recessive genetic hemorrhagic disorder characterized by deficient or absent plasma clotting factor VIII...
Increased risk of vaso-occlusive crisis in patients with sickle cell disease treated with crizanlizumab: A real-world analysis using the trinetx database
Abstract Introduction: Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by mutations in the β-globin ge...
The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma
Abstract Introduction: CAR T therapy has revolutionized treatment landscape for patients with relapsed refractory (R/R) non-Hodgkin's lympho...
From bench to IND: Validation of TSLPR CAR T-cells reveal discrepancies in detection modalities and inform dose selection for a Phase 1 clinical trial in relapsed/refractory CRLF2-rearranged B-ALL patients.
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 and CD22 have achieved remarkable success in patients...
CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity
Abstract Introduction CD19-directed CAR-T cells (CAR19) induce responses in relapsed/refractory (R/R) mantle cell (MCL) and follicular lymph...
Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
Abstract Despite significant improvements in multiple myeloma (MM) therapy, the outcome of patients (pts) remain heterogeneous. Prognostic f...
Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Abstract Introduction: Talquetamab is the first approved bispecific antibody targeting GPRC5D and CD3 for the treatment of patients with rel...